The event takes place tomorrow (14 November)
Interest in Near Patient Testing (NPT) continues to gain momentum as it has a major role to play in redesigning services around the needs of the patient. Robyn Meurant will participate in the Near Patient Testing working group on November 14, as it aims to understand the current market for near patient testing and identify the challenges that are likely to impair progress in this exciting area. The group has recently published a document highlighting the value of near patient testing and the significant benefits of wider adoption to patient outcomes.
The British In Vitro Diagnostics Association (BIVDA) is the national industry association for companies with major involvement and interest in the in vitro diagnostics (IVD) industry. BIVDA represents over 95% of IVD manufacturers and distributors in the UK, from British start-up companies to UK subsidiaries of multinational corporations. BIVDA members currently employ over 8,500 people in the UK, with a total industry turnover of approximately £820 million.
Robyn Meurant has more than 30 years of experience in the field of IVDs, as a laboratory scientist and as a regulator with the Australian Therapeutic Goods Administration (TGA) and with World Health Organization (WHO) Prequalification. Ms. Meurant began her career working in several large diagnostic laboratories in the role of senior scientist. In her position at TGA, Ms. Meurant assisted in developing the new regulatory framework for IVDs. With WHO, she served as the lead technical officer for application evaluation and dossier assessment, and as lead for the development of guidance and technical specifications for IVDs in the scope of WHO Prequalification. In addition, she has contributed to standards development and has been a source of expert advice to the Australian government on IVDs. In 2009 she was awarded the Distinguished Service Award by the Australian Society for Microbiology.